Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trialMehreen S. Datoo, Nsajigwa Misidai, Alassane Dicko et al.|The Lancet|2024Cited by 345
Pyronaridine–artesunate or dihydroartemisinin–piperaquine combined with single low-dose primaquine to prevent Plasmodium falciparum malaria transmission in Ouélessébougou, Mali: a four-arm, single-blind, phase 2/3, randomised trialWilliam J. Stone, Alassane Dicko, Harouna M Soumaré et al.|The Lancet Microbe|2021Cited by 38
Persistence of mRNA indicative of Plasmodium falciparum ring-stage parasites 42 days after artemisinin and non-artemisinin combination therapy in naturally infected MaliansAlmahamoudou Mahamar, Michelle E. Roh, Kjerstin Lanke et al.|Malaria Journal|2021Cited by 7
Recent malaria does not substantially impact COVID-19 antibody response or rates of symptomatic illness in communities with high malaria and COVID-19 transmission in Mali, West AfricaJohn Woodford, Patrick E. Duffy, Issaka Sagara et al.|Frontiers in Immunology|2022Cited by 7